menu
    • menu
    [{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ibutamoren","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Double Point Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals for Ibutamoren

    Menu

    Ibutamoren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Double Point Ventures

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Lumos Acquired by Double Point Ventures After Tender Offer Completion

                            Details : Lumos’ lead therapeutic candidate, LUM-201 (ibutamoren ), is a novel, oral growth hormone (GH) secretagogue, currently being evaluated in multiple Phase 2 in Pediatric Growth Hormone Deficiency.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Double Point Ventures

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Double Point Ventures

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Lumos Pharma to Go Private with Double Point Ventures At $4.25/Share

                            Details : Lumos’ lead therapeutic candidate, LUM-201 (ibutamoren ), is a novel, oral growth hormone (GH) secretagogue, currently being evaluated in multiple Phase 2 in Pediatric Growth Hormone Deficiency.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Double Point Ventures

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

                            Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 05, 2023

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate ...

                            Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2023

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KOL Review of Lumos Pharma™s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for M...

                            Details : LUM-201, an oral growth hormone secretagogue, has a unique mechanism of action, targeting specific receptors on the pituitary and hypothalamus to stimulate the natural pulsatile secretion of growth hormone for moderate idiopathic PGHD patients.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderat...

                            Details : LUM-201, an oral growth hormone stimulating small molecule demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2022

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM...

                            Details : LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adu...

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

                            Details : Lumos Pharma intends to analyze these interim datasets separately and also perform a combined analysis to increase the number of subjects in the top two LUM-201 dose cohorts.

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2022

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Op...

                            Details : The subgroup of the Merck 020 trial specifically examined the effect LUM-201 had on the pulsatile secretion of growth hormone (GH) over 24 hours in patients with PGHD after 6 months of treatment with LUM-201, compared to that patient’s baseline GH secr...

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2021

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Lumos Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lumos Pharma's Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues

                            Details : Poster 7102 presents an analysis of data from a prior clinical study comparing the peak growth hormone (GH) response of LUM-201 to that of standard GH secretagogues in children naïve-to-treatment, previously diagnosed with growth hormone deficiency (GHD...

                            Product Name : LUM-201

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2021

                            Lead Product(s) : Ibutamoren

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth